ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Speedway Motorsports Inc
19.78
0.0000
成交量:
- -
成交額:
- -
市值:
8.08億
市盈率:
21.28
高:
19.78
開:
19.78
低:
19.78
收:
19.78
52周最高:
19.90
52周最低:
13.47
股本:
4,085.39萬
流通股本:
1,124.32萬
量比:
- -
換手率:
- -
股息:
0.60
股息率:
3.03%
每股收益(TTM):
0.9294
每股收益(LYR):
0.9887
淨資產收益率:
4.03%
總資產收益率:
2.83%
市淨率:
0.85
市盈率(LYR):
20.01
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
諾誠健華第二代泛TRK抑制劑ICP-723完成首例青少年患者給藥
美通社
·
2022/10/31
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TRK"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TRK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRK\",,,,,undefined,":{"symbol":"TRK","market":"US","secType":"STK","nameCN":"Speedway Motorsports Inc","latestPrice":19.78,"timestamp":1569009600000,"preClose":19.78,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":11243173,"shares":40853902,"eps":0.929399,"marketStatus":"已收盤","change":0,"latestTime":"09-20 16:00:00 EDT","open":19.78,"high":19.78,"low":19.78,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.929399,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":793515600000,"exchange":"NYSE","adjPreClose":19.78,"dividendRate":0.030334,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRK\",,,,,undefined,":{"symbol":"TRK","floatShares":11243173,"roa":"2.83%","roe":"4.03%","lyrEps":0.988731,"shares":40853902,"dividePrice":0.6,"high":19.78,"amplitude":0,"preClose":19.78,"low":19.78,"week52Low":13.47,"pbRate":"0.85","week52High":19.9,"institutionHeld":0.2191,"latestPrice":19.78,"eps":0.929399,"divideRate":0.030334,"volume":0,"delay":0,"ttmEps":0.929399,"open":19.78,"prevYearClose":19.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRK\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-08-14","symbol":"TRK","amount":0.15,"name":"Speedway Motorsports Inc","payableDate":"2019-08-15","currency":"USD","type":"dividend","dateTimestamp":1565755200000},{"market":"US","date":"2019-07-31","symbol":"TRK","fiscalQuarterEnding":"2019/06","expectedEps":0.47,"name":null,"time":"盤前","type":"earning","dateTimestamp":1564545600000,"reportTimeType":"pre","actualEps":0.75},{"market":"US","date":"2019-05-14","symbol":"TRK","amount":0.15,"name":"Speedway Motorsports Inc","payableDate":"2019-05-15","currency":"USD","type":"dividend","dateTimestamp":1557806400000},{"market":"US","date":"2019-05-01","symbol":"TRK","fiscalQuarterEnding":"2019/03","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1556683200000,"reportTimeType":"pre","actualEps":0.22},{"market":"US","date":"2019-03-13","symbol":"TRK","fiscalQuarterEnding":"2018/12","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1552449600000,"reportTimeType":"pre","actualEps":-0.27}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRK\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-27","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-11","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-08-11","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-11-09","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2018-02-28","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRK\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRK\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2279765208","title":"諾誠健華第二代泛TRK抑制劑ICP-723完成首例青少年患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2279765208","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2279765208?lang=zh_tw&edition=fundamental","pubTime":"2022-10-31 11:23","pubTimestamp":1667186580,"startTime":"0","endTime":"0","summary":"北京2022年10月31日 /美通社/ -- 生物医药高科技公司诺诚健华今天宣布,公司自主研发的第二代泛TRK小分子抑制剂ICP-723在中山大学肿瘤防治中心儿童肿瘤科完成首例青少年患者给药,这也是ICP-723在成人患者中显示良好安全性和有效性后,首次在青少年患者中开展临床研究。诺诚健华也已经在美国进行ICP-723的临床研究,目前在第一个剂量组尚未观察到剂量限制性毒性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3919319_ZH19319_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ICP","09969","688428","TRK","BK0239","BK1574","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TRK\",params:#limit:6,delay:false,,,undefined,":[]}}